MedTrace Logo

The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure

NCT02284230 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-08-24

No results posted yet for this study

Summary

The present study will examine the effects of liraglutide treatment during 26 weeks on several cardiovascular risk factors in patients with prediabetes and end-stage renal disease (ESRD). The primary objective is to determine the efficacy of the treatment on glucose tolerance evaluated during a 3h 75g-oral glucose tolerance test (OGTT). Secondary objectives include various clinical and biochemical cardiovascular and safety parameters.

We hypothesise that treatment with liraglutide can improve glucose tolerance in prediabetic patients with ESRD by normalizing plasma glucose excursions during an OGTT and ameliorate other cardiovascular risk factors.

Conditions

  • Kidney Failure, Chronic
  • Prediabetic State

Interventions

DRUG

Liraglutide

DRUG

Placebo

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • The GCP unit at Copenhagen University Hospital

    collaborator UNKNOWN

  • Bo Feldt-Rasmussen

    lead OTHER

Principal Investigators

  • Bo Feldt-Rasmussen, Prof,MD,DMSc · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02284230 on ClinicalTrials.gov